Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMA101 product · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| IMA101 product only (Cohort 1) | EXPERIMENTAL | * Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide * Infusion of the IMA101 T-cell product(s) * Post-infusion administration of low-dose recombinant human interleukin-2 |
| IMA101 product + atezolizumab (Cohort 2) | EXPERIMENTAL | * Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide * Infusion of the IMA101 T-cell product(s) * Post-infusion administration of low-dose recombinant human interleukin-2 * Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year |
| Name | Type | Description |
|---|---|---|
| Fludarabine | DRUG | Fludarabine infusion |
| Cyclophosphamide | DRUG | Cyclophosphamide infusion |
| IMA101 product | BIOLOGICAL | i.v. infusion of IMA101 product(s). |
| Recombinant human interleukin-2 | BIOLOGICAL | Low dose IL-2 Infusion for two weeks |
| IMADetect | DIAGNOSTIC_TEST | IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only. |
| Atezolizumab | DRUG | Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion. |
Inclusion Criteria: 1. Patients must have pathologically confirmed advanced/metastatic cancer prior to enrollment. 2. HLA phenotype positive. 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 4. Life expectancy \> 6 months prior to enrollment. 5. Patient is a candidate for a maxi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
IMA101 product is an investigational monoclonal antibody being developed for the treatment of cancer, specifically solid tumors. It is currently in Phase 1 clinical development and has been studied in a completed clinical trial involving patients with solid cancers.
IMA101 product is being developed by Immatics N.V., a biopharmaceutical company. Immatics is publicly traded on the stock market under the ticker symbol IMTX.
IMA101 product is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 clinical trial for IMA101 product has been completed.
IMA101 product has been studied in one clinical trial with the identifier NCT02876510, titled 'ACTolog in Patients With Solid Cancers.' This was a Phase 1, controlled trial conducted in the United States with 38 participants, and it has been completed.
IMA101 product is associated with the clinical trial titled 'ACTolog in Patients With Solid Cancers,' which suggests that ACTolog may be an alternative name for IMA101 product. The trial NCT02876510 evaluated IMA101 product in patients with solid tumors.